Shenzhen Salubris Pharmaceuticals: Announcement on the Progress of JK06 Overseas Clinical Trial
Shenzhen Salubris Pharmaceuticals: Announcement on the approval of clinical trial notification for new indications of Enadastron.
Shenzhen Salubris Pharmaceuticals: Announcement regarding the receipt of the clinical trial approval notice for SAL0120.
Shenzhen Salubris Pharmaceuticals: Announcement on the completion of non-trading transfer and repurchase of shares for the third phase of employee stock ownership plan
Shenzhen Salubris Pharmaceuticals: Announcement regarding the pharmaceutical registration certificate for Benzoic Acid Voglibose Tablets (Xinlitin)
Shenzhen Salubris Pharmaceuticals: Announcement regarding the acceptance of the SAL056 listing application.
Shenzhen Salubris Pharmaceuticals: Asset management contract for Guolian Salubris No. 3 Employee Shareholding Single Asset Management Plan.
Shenzhen Salubris Pharmaceuticals: Announcement Regarding the Release of Pledged Shares by the Controlling Shareholder.
Shenzhen Salubris Pharmaceuticals: Announcement Regarding the Selection of the Management Committee for the Third Phase of Employee Stock Ownership Plan
Shenzhen Salubris Pharmaceuticals: Notice of the expiration of the lock-up period for the second phase of employee shareholding plan.
Shenzhen Salubris Pharmaceuticals: Announcement of Annual Equity Distribution Implementation in 2023
Shenzhen Salubris Pharmaceuticals: Announcement regarding Sun Company providing guarantee for its subsidiary.
Shenzhen Salubris Pharmaceuticals: Notice on obtaining a drug registration certificate for alisartan ester amlodipine tablets (foritan)
Shenzhen Salubris Pharmaceuticals: Announcement on shareholders donating part of the company's shares free of charge
Shenzhen Salubris Pharmaceuticals: Announcement on shareholders donating part of the company's shares free of charge to complete the transfer
Shenzhen Salubris Pharmaceuticals: Announcement on the controlling shareholder's partial share pledge and cancellation of the pledge
Xinlitai: First Quarter Report 2024
Xinlitai: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Xinlitai: Announcement of Resolutions of the Third Meeting of the 6th Board of Directors
Xinlitai: Announcement on capital increase for subsidiary Salubris Biotherapeutics, Inc.
No Data